Form 4: Disc Medicine Director Liam Ratcliffe Granted 10,000 Stock Options

Disc Medicine, Inc. Director Liam Ratcliffe was granted 10,000 stock options with an exercise price of $50.86, aligning his interests with shareholder value.

Summary

• Liam Ratcliffe, a Director of Disc Medicine, Inc. (IRON), was granted 10,000 stock options.
• The options have an exercise price of $50.86 per share.
• The grant date for these options was June 11, 2025.
• The options will expire on June 10, 2035.
• Vesting occurs upon the earlier of the Company's 2026 annual meeting of stockholders or the one-year anniversary of the grant date (June 11, 2026), contingent on Mr. Ratcliffe's continued service.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive signal as it aligns the director's interests with shareholder value, incentivizing long-term performance. It's a routine compensation event, so the positive impact is moderate rather than significant.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• This is a standard form of executive and director compensation, indicating normal corporate governance practices.

Negatives

• No immediate negative implications are apparent from this routine insider transaction filing.

Future Outlook

The stock options granted to Director Liam Ratcliffe are set to vest upon the earlier of the Company's 2026 annual meeting or the one-year anniversary of the grant date (June 11, 2026), subject to his continued service, providing a future incentive for long-term performance.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to align the interests of board members with shareholder value creation. This filing reflects a routine compensation event within the sector.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, including those in the biotech sector like Disc Medicine, Inc.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is typical for director equity grants, similar to practices observed at companies such as Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors.
• The exercise price being at or above the market price on the grant date (implied by the nature of a stock option grant) is also standard, ensuring the incentive is tied to future stock price appreciation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.

Next Steps

• The stock options will vest upon the earlier of the Company's 2026 annual meeting or the one-year anniversary of the grant date (June 11, 2026).
• Liam Ratcliffe's continued service as a director is required for the options to vest.

Key Dates

Keywords

Disc Medicine, IRON, Stock Options, Insider Transaction, Form 4, Director Compensation, Liam Ratcliffe, Equity Grant